Article information
Abstract
Parenteral iron is a useful and safe therapeutic measure to treat anaemia, and is a proven clinical alternative to blood transfusion. This review article summarises the main characteristics of the different formulations of parenteral iron, their advantages, indications, dosages, and adverse effects. Moreover, we analyse some of the most important published articles on parenteral iron therapy in general surgery and other surgical specialties, as well as providing information about new formulations that will soon be available.
Keywords:
Intravenous iron
Iron therapy
Anaemia
Resumen
El hierro intravenoso representa una medida terapéutica eficaz y segura para corregir la anemia, y constituye una alternativa respecto a la transfusión sanguínea clínicamente demostrada. El presente artículo de revisión resume las principales características de los distintos preparados de hierro parenteral, sus ventajas, indicaciones, dosificación y efectos adversos. Asimismo, se analizan algunos de los principales estudios publicados sobre ferroterapia parenteral en cirugía general y especialidades quirúrgicas afines, y se avanzan algunos datos sobre las nuevas formulaciones próximamente disponibles.
Palabras clave:
Hierro intravenoso
Ferroterapia
Anemia
Full text is only aviable in PDF
References
[1.]
E. Bisbe, C. Rodríguez, A. Ruiz, M. Sáez, J. Castillo, X. Santiveri.
Uso preoperatorio de hierro endovenoso Una nueva terapéutica en medicina transfusional.
Rev Esp Anestesiol Reanim, 52 (2005), pp. 536-540
[2.]
C. Gasche, A. Berstad, R. Befrits, C. Beglinger, A. Dignass, K. Erichsen, et al.
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases.
Inflamm Bowel Dis, 13 (2007), pp. 1545-1553
[3.]
M. Muñoz, C. Breymann, J.A. García-Erce, S. Gómez-Ramírez, J. Comin, E. Bisbe.
Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion.
Vox Sang, 94 (2008), pp. 172-183
[4.]
H. Gaskell, S. Derry, R. Andrew Moore, H.J. McQuay.
Prevalence of anaemia in older persons: Systematic review.
BMC Geriatr, 8 (2008), pp. 1
[5.]
K.V. Patel.
Epidemiology of anemia in older adults.
Semin Hematol, 45 (2008), pp. 210-217
[6.]
X. Dong, C. Mendes de León, A. Artz, Y. Tang, R. Shah, D. Evans.
A population-based study of hemoglobin, race, and mortality in elderly persons.
J Gerontol A Biol Sci Med Sci, 63 (2008), pp. 873-878
[7.]
F. Landi, A. Russo, P. Danese, R. Liperoti, C. Barillaro, R. Bernabei, et al.
Anemia status, hemoglobin concentration, and mortality in nursing home older residents.
J Am Med Dir Assoc, 8 (2007), pp. 322-327
[8.]
P. Beris, M. Muñoz, J.A. García-Erce, D. Thomas, A. Maniatis, P. van der Linden.
Perioperative anaemia management: Consensus statement on the role of intravenous iron.
Br J Anaesth, 100 (2008), pp. 599-604
[9.]
I. Bates, G.K. Chapotera, S. McKew, N. Van den Broek.
Maternal mortality in sub-Saharan Africa: The contribution of ineffective blood transfusion services.
BJOG, 115 (2008), pp. 1331-1339
[10.]
J.A. Nissim, J.M. Robson.
Preparation and standardization of saccharated iron oxide for intra venous administration.
Lancet, 1 (1949), pp. 686-689
[11.]
I.M. Baird, D.A. Podmore.
Intramuscular iron therapy in irondeficiency anaemia.
Lancet, 267 (1954), pp. 942-946
[12.]
M. Auerbach, D. Coyne, H. Ballard.
Intravenous iron: From anathema to standard of care.
Am J Hematol, 83 (2008), pp. 580-588
[13.]
A. Serrablo, E. Urbieta, J. Carcelén-Andrés, J. Ruiz, J. Rodrigo, M. Izuel, et al.
Hierro por vía intravenosa en cirugía general.
Cir Esp, 78 (2005), pp. 195-197
[14.]
O.M. Theusinger, P.F. Leyvraz, U. Schanz, B. Seifert, D.R. Spahn.
Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: Efficacy and limits: A prospective study.
Anesthesiology, 107 (2007), pp. 923-927
[15.]
J. Cuenca, J.A. García-Erce, M. Muñoz, M. Izuel, A.A. Martínez, A. Herrera.
Patients with pertrochanteric hip fracture may benefit from preoperative intravenous iron therapy: A pilot study.
Transfusion, 44 (2004), pp. 1447-1452
[16.]
F. de la Morena, J.P. Gisbert.
Anemia and inflammatory bowel disease.
Rev Esp Enferm Dig, 100 (2008), pp. 285-293
[17.]
D.T. Lee, S.C. Robinson.
Single total-dose intravenous infusion of iron-dextran.
Can Med Assoc J, 97 (1967), pp. 377-379
[18.]
M. Auerbach, H. Ballard.
Intravenous iron in oncology.
J Natl Compr Canc Netw, 6 (2008), pp. 585-592
[19.]
J.E. Novak, L.A. Szczech.
Triumph and tragedy: Anemia management in chronic kidney disease.
Curr Opin Nephrol Hypertens, 17 (2008), pp. 580-588
[20.]
D.O. Okonko, A. Grzeslo, T. Witkowski, A.K. Mandal, R.M. Slater, M. Roughton, et al.
Effect of intravenous iron sucrose on exercise tolerance in anemic and non anemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial.
J Am Coll Cardiol, 51 (2008), pp. 103-112
[21.]
Zilberman M, Silverberg DS, Schwartz D, Oksenberg A. Restless Legs Syndrome (RLS) in anemic patients with Congestive Heart Failure and Chronic Renal Failure: Lack of effect of anemia treatment. Int J Cardiol. In press 2009.
[22.]
G. Mak, N.F. Murphy, K. McDonald.
Anemia in heart failure: To treat or not to treat?.
Curr Treat Options Cardiovasc Med, 10 (2008), pp. 455-464
[23.]
G. Chandler, J. Harchowal, I.C. Macdougall.
Intravenous iron sucrose: Establishing a safe dose.
Am J Kidney Dis, 38 (2001), pp. 988-991
[24.]
B.S. Spinowitz, A.T. Kausz, J. Baptista, S.D. Noble, R. Sothinathan, M.V. Bernardo, et al.
Ferumoxytol for treating iron deficiency anemia in CKD.
J Am Soc Nephrol, 19 (2008), pp. 1599-1605
[25.]
A. Singh, T. Patel, J. Hertel, M. Bernardo, A. Kausz, L. Brenner.
Safety of ferumoxytol in patients with anemia and CKD.
Am J Kidney Dis, 52 (2008), pp. 907-915
[26.]
N. Ternes, B. Scheiber-Mojdehkar, G. Landgraf, H. Goldenberg, B. Sturm.
Iron availability and complex stability of iron hydroxyethyl starch and iron dextran a comparative in vitro study with liver cells and macrophages.
Nephrol Dial Transplant, 22 (2007), pp. 2824-2830
[27.]
M. Muñoz, S.R. Leal-Noval, J.A. García-Erce, E. Naveira.
Prevalencia y tratamiento de la anemia en el paciente crítico.
Med Intensiva, 31 (2007), pp. 388-398
[28.]
D.B. van Wyck, B.G. Danielson, G.R. Aronoff.
Making sense: A scientific approach to intravenous iron therapy.
J Am Soc Nephrol, 15 (2004), pp. S91-S92
[29.]
M. Muñoz Gómez, A. Campos Garríguez, J.A. García Erce, G. Ramírez Ramírez.
Fisiopatología del metabolismo del hierro: implicaciones diagnósticas y terapéuticas.
Nefrología, 25 (2005), pp. 9-19
[30.]
D.H. Henry.
The role of intravenous iron in cancer-related anemia.
Oncology (Williston Park), 20 (2006), pp. 21-24
[31.]
J. Cuenca, J.A. García-Erce, M. Muñoz.
Efficacy of intravenous iron sucrose administration for correcting preoperative anemia in patients scheduled for major orthopedic surgery.
Anesthesiology, 109 (2008), pp. 151-152
[32.]
N. Padullés, F. Sala, L. Mendarte, J. Monterde.
Fisiopatología del hierro. Criterios de indicación de hierro parenteral, disponibilidad y pautas de administración. Revisión de la situación actual.
Pharmaceutical Care España, 8 (2006), pp. 199-252
[33.]
A.M. Ganzoni.
Intravenous iron-dextran: Therapeutic and experimental possibilities.
Schweiz Med Wochenschr, 100 (1970), pp. 301-303
[34.]
J. Cuenca, J.A. García-Erce, A.A. Martínez, V.M. Solano, J. Molina, M. Muñoz.
Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: Preliminary data.
Arch Orthop Trauma Surg, 125 (2005), pp. 342-347
[35.]
S. Beshara, J. Sörensen, M. Lubberink, V. Tolmachev, B. Langström, G. Antoni, et al.
Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography.
Br J Haematol, 120 (2003), pp. 853-859
[36.]
S. Beshara, H. Lundqvist, J. Sundin, M. Lubberink, V. Tolmachev, S. Valind, et al.
Pharmacokinetics and red cell utilization of iron (III) hydroxide-sucrose complex in anaemic patients: A study using positron emission tomography.
Br J Haematol, 104 (1999), pp. 296-302
[37.]
S. Kulnigg, S. Stoinov, V. Simanenkov, L.V. Dudar, W. Karnafel, L.C. Garcia, et al.
A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial.
Am J Gastroenterol, 103 (2008), pp. 1182-1192
[38.]
O. Schröder, M. Schrott, I. Blumenstein, J. Jahnel, A.U. Dignass, J. Stein.
A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding.
Z Gastroenterol, 42 (2004), pp. 663-667
[39.]
D.A. Blaustein, M.H. Schwenk, J. Chattopadhyay, H. Singh, R. Daoui, R. Gadh.
The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease.
Kidney Int Suppl, (2003), pp. S72-S77
[40.]
C. Gasche, M.C. Lomer, I. Cavill, G. Weiss.
Iron, anaemia, and inflammatory bowel diseases.
Gut, 53 (2004), pp. 1190-1197
[41.]
A.R. Nissenson, C. Charytan.
Controversies in iron management.
Kidney Int Suppl, (2003), pp. S64-S71
[42.]
M. Izuel-Rami, J. Cuenca Espiérrez, J.A. García-Erce, M. Gómez-Barrera, J. Carcelén Andrés, M.J. Rabanaque Hernández.
Efectividad de distintas pautas de tratamiento de la anemia perioperatoria en pacientes ancianos con fractura de cadera.
Farm Hosp, 29 (2005), pp. 250-257
[43.]
E. Reynoso-Gómez, V. Salinas-Rojas, A. Lazo-Langner.
Eficacia y seguridad de la infusión total de hierro en el tratamiento de la anemia ferropriva en adultos no gestantes.
Rev Invest Clin, 54 (2002), pp. 12-20
[44.]
K.M. Patel, J.A. Tulloch.
Total dose imferon (iron-dextran complex) infusion therapy in severe hookworm anaemia.
Br Med J, 2 (1967), pp. 605-607
[45.]
R. Ayub, N. Tariq, M.M. Adil, M. Iqbal, A. Junaid, T. Jaferry.
Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy.
J Coll Physicians Surg Pak, 18 (2008), pp. 424-427
[46.]
G.R. Aronoff.
Safety of intravenous iron in clinical practice: Implications for anemia management protocols.
J Am Soc Nephrol, 15 (2004), pp. S99-S106
[47.]
T.B. Drüeke, Z.A. Massy.
Intravenous iron: How much is too much?.
J Am Soc Nephrol, 16 (2005), pp. 2833-2835
[48.]
G.M. Chertow, P.D. Mason, O. Vaage-Nilsen, J. Ahlmén.
Update on adverse drug events associated with parenteral iron.
Nephrol Dial Transplant, 21 (2006), pp. 378-382
[49.]
J. Yee, A. Besarab.
Iron sucrose: The oldest iron therapy becomes new.
Am J Kidney Dis, 40 (2002), pp. 1111-1121
[50.]
R. Leal, I. Alberca, M.S. Asuero, J.L. Bóveda, N. Carpio, E. Contreras, et al.
Documento «Sevilla» de consenso sobre alternativas a la transfusión de sangre alogénica.
Med Clin (Barc), 127 (2006), pp. 3-20
[51.]
L. Schaefer, R.M. Schaefer.
A primer on iron therapy.
Nephrol Dial Transplant, 22 (2007), pp. 2429-2431
[52.]
S. Torres, Y.H. Kuo, K. Morris, R. Neibart, J.B. Holtz, J.M. Davis.
Intravenous iron following cardiac surgery does not increase the infection rate.
Surg Infect (Larchmt), 7 (2006), pp. 361-366
[53.]
A. Ozdemir, B. Yalinbas, U. Selamet, M. Eres, B. Murat, R.U. Gürsu, et al.
Relationship between iron replacement and hepatic functions in hepatitis C virus-positive chronic haemodialysis patients.
Nephrology (Carlton), 10 (2005), pp. 433-437
[54.]
I. Kurihara, T. Saito.
Significance of parenteral iron administration for HCV-positive hemodialysis patients.
Nippon Jinzo Gakkai Shi, 44 (2002), pp. 389-395
[55.]
D.B. van Wyck, M.G. Martens, M.H. Seid, J.B. Baker, A. Mangione.
Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: A randomized controlled trial.
Obstet Gynecol, 110 (2007), pp. 267-278
[56.]
C. Breymann, F. Gliga, C. Bejenariu, N. Strizhova.
Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia.
Int J Gynaecol Obstet, 101 (2008), pp. 67-73
[57.]
G. Perewusnyk, R. Huch, A. Huch, C. Breymann.
Parenteral iron therapy in obstetrics: 8 years experience with iron-sucrose complex.
Br J Nutr, 88 (2002), pp. 3-10
[58.]
N. Kosmadakis, E. Messaris, A. Maris, S. Katsaragakis, E. Leandros, M.M. Konstadoulakis, et al.
Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: Prospective randomized double-blind study.
Ann Surg, 237 (2003), pp. 417-421
[59.]
Y. Tsuji, J. Kambayashi, E. Shiba, M. Sakon, T. Kawasaki, T. Mori.
Effect of recombinant human erythropoietin on anaemia after gastrectomy: A pilot study.
Eur J Surg, 161 (1995), pp. 29-33
[60.]
M. Braga, L. Gianotti, A. Vignali, O. Gentilini, P. Servida, C. Bordignon, et al.
Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract.
Br J Surg, 82 (1995), pp. 1637-1640
[61.]
P. Beris, A. Maniatis.
Role of intravenous iron therapy in anemia management: State of the art.
Semin Hematol, 43 (2006), pp. S1-S2
[62.]
M. Auerbach.
Should intravenous iron be the standard of care in oncology?.
J Clin Oncol, 26 (2008), pp. 1579-1581
[63.]
P. Pedrazzoli, A. Farris, S. Del Prete, F. del Gaizo, D. Ferrari, C. Bianchessi, et al.
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetina alpha.
J Clin Oncol, 26 (2008), pp. 1619-1625
[64.]
Y.T. Kim, S.W. Kim, B.S. Yoon, H.J. Cho, E.J. Nahm, S.H. Kim, et al.
Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy.
Gynecol Oncol, 105 (2007), pp. 199-204
[65.]
M. Auerbach, H. Ballard, J.R. Trout, M. McIlwain, A. Ackerman, H. Bahrain, et al.
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial.
J Clin Oncol, 22 (2004), pp. 1301-1307
[66.]
G.R. Aronoff, W.M. Bennett, S. Blumenthal, C. Charytan, J.P. Pennell, J. Reed, United States Iron Sucrose (Venofer) Clinical Trials Group, et al.
Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens.
Kidney Int, 66 (2004), pp. 1193-1198
[67.]
M. Braga, L. Gianotti, O. Gentilini, A. Vignali, L. Corizia, V. Di Carlo.
Erythropoiesis after therapy with recombinant human erythropoietin: a dose-response study in anemic cancer surgery patients.
Vox Sang, 76 (1999), pp. 38-42
[68.]
O. Nyvad, H. Danielsen, S. Madsen.
Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients.
Lancet, 344 (1994), pp. 1305-1306
[69.]
A.K. Al-Momen, S.O. Huraib, A.H. Mitwalli, J. Al-Wakeel, M.J.M.S. Al-Yamani, H. Abu-Aisha, et al.
Intravenous iron saccharate in hemodialysis patients receiving r-HuEPO.
Saudi J Kidney Dis Transplant, 5 (1994), pp. 168-172
[70.]
B. Rozen-Zvi, A. Gafter-Gvili, M. Paul, L. Leibovici, O. Shpilberg, U. Gafter.
Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis.
Am J Kidney Dis, 52 (2008), pp. 897-906
[71.]
H.I. Feldman, M. Joffe, B. Robinson, J. Knauss, B. Cizman, W. Guo, et al.
Administration of parenteral iron and mortality among hemodialysis patients.
J Am Soc Nephrol, 15 (2004), pp. 1623-1632
[72.]
A.K. Al-Momen, A. Al-Meshari, L. Al-Nuaim, A. Saddique, Z. Abotalib, T. Khashogji, et al.
Intravenous iron sucrose complex in the treatment of iron deficiency anemia Turing pregnancy.
Eur J Obstet Gynecol Reprod Biol, 69 (1996), pp. 121-124
[73.]
M.H. Seid, R.J. Derman, J.B. Baker, W. Banach, C. Goldberg, R. Rogers.
Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: A randomized controlled clinical trial.
Am J Obstet Gynecol, 199 (2008),
[74.]
V. Pinsk, J. Levy, A. Moser, B. Yerushalmi, J. Kapelushnik.
Efficacy and safety of intravenous iron sucrose therapy in a group of children with iron deficiency anemia.
Isr Med Assoc J, 10 (2008), pp. 335-338
[75.]
C. Gasche, C. Dejaco, T. Waldhoer, W. Tillinger, W. Reinisch, G.F. Fueger, et al.
Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial.
Ann Intern Med, 126 (1997), pp. 782-787
[76.]
C. Gasche, T. Waldhoer, T. Feichtenschlager, C. Male, A. Mayer, C. Mittermaier, Austrian Inflammatory Bowel Diseases Study Gro-up, et al.
Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia.
Am J Gastroenterol, 96 (2001), pp. 2382-2387
[77.]
G. Bodemar, S. Kechagias, S. Almer, B.G. Danielson.
Treatment of anaemia in inflammatory bowel disease with iron sucrose.
Scand J Gastroenterol, 39 (2004), pp. 454-458
[78.]
M. Muñoz, E. Naveira, J. Seara, J.H. Palmer, J. Cuenca, J.A. García-Erce.
Role of parenteral iron in transfusion requirements after total hip replacement. A pilot study.
Transfus Med, 16 (2006), pp. 137-142
[79.]
J. Cuenca, J.A. García-Erce, F. Martínez, L. Pérez-Serrano, A. Herrera, M. Muñoz.
Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogeneic blood after knee replacement surgery.
Transfusion, 46 (2006), pp. 1112-1119
[80.]
J.A. García-Erce, J. Cuenca, M. Muñoz, M. Izuel, A.A. Martínez, A. Herrera, et al.
Perioperative stimulation of erythropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study.
Vox Sang, 88 (2005), pp. 235-243
[81.]
G. Gargano, G. Polignano, M. de Lena, M. Brandi, V. Lorusso, G. Fanizza.
The utility of a growth factor: r-HuEPO as a treatment for preoperative autologous blood donation in gynecological tumor surgery.
Int J Oncol, 14 (1999), pp. 157-160
[82.]
L. Bastit, A. Vandebroek, S. Altintas, B. Gaede, T. Pintér, T.S. Suto, et al.
Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
J Clin Oncol, 26 (2008), pp. 1611-1618
Copyright © 2009. Asociación Española de Cirujanos
